Prevention

Preprint data from a real-world evidence assessment, as well as preliminary reports from a 2-dose trial, support the company's pursuit for FDA authorization of a second COVID-19 vaccine dose.

Though efficacy waned over months, protection from symptomatic and severe COVID-19 remained significant, with no new adverse event risks observed.

A neighborhood-level assessment of major cities show areas impacted the most by historic COVID-19 deaths are significantly less vaccinated.

New Imbokodo findings show a 4-dose regimen was only about 25% effective in preventing HIV in at-risk women, hindering progress for the vaccine.

An Israel study estimates vaccinated persons' risk of side effects including myocarditis, relative to the risk brought on by SARS-CoV-2 infection.

The submission comes day after BNT162b2 became the first fully approved COVID-19 vaccine by the FDA.

The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.

The Biden administration reportedly hopes for FDA-authorized booster doses for the adult general population in the next month.

The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.

Donald Alcendor, PhD, shares expert perspective on the newest FDA authorization, as well as what a full COVID-19 vaccine approval would mean for US immunization.

The move will offer an extra boost of immunity for patients with compromised immune systems, including organ transplant recipients.

An England study shows the Pfizer-BioNTech and AstraZeneca vaccines remain effective in reducing symptomatic disease risk.

Considering the care team members who need to help infectious disease specialists and pharmacists carry the stewardship torch.

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

The report of promising phase 2 findings align with word that an FDA submission will be delayed until later this year.

Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

The prophylaxis showed non-inferiority across shared serotypes with an available 13-valent vaccine in its indication-supporting data.

The designation moves the companies' PDUFA date up to January 2022, when BNT162b2 may become the first regulated COVID-19 vaccine.

The challenging search for a metric that effectively evaluates an ASP’s direct impact on appropriate antimicrobial use and improved patient outcomes.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

Experts suggest the vaccine, if regulated by the FDA, would benefit the US as a booster dose to combat waning immunity against emerging variants.

A prospective study suggest co-infections and secondary infections are infrequent among COVID-19 patients, warranting the need for improved stewardship.

New research from Emory show a significant difference in institutional antibiotic prescribing after education on the value of PCT testing in infected patients last year.

The newest data for the real-world assessment show the mRNA vaccine provides greater immunogenicity in persons aged 12-15 years old than in young adults.